KR20230003308A - 듀테트라베나진의 유사체, 이의 제조 및 용도 - Google Patents

듀테트라베나진의 유사체, 이의 제조 및 용도 Download PDF

Info

Publication number
KR20230003308A
KR20230003308A KR1020227043234A KR20227043234A KR20230003308A KR 20230003308 A KR20230003308 A KR 20230003308A KR 1020227043234 A KR1020227043234 A KR 1020227043234A KR 20227043234 A KR20227043234 A KR 20227043234A KR 20230003308 A KR20230003308 A KR 20230003308A
Authority
KR
South Korea
Prior art keywords
dutetrabenazine
compound
pharmaceutical composition
concentration
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227043234A
Other languages
English (en)
Korean (ko)
Inventor
쳉지 장
짐 케르
Original Assignee
오스펙스 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스펙스 파마슈티칼스, 인코포레이티드 filed Critical 오스펙스 파마슈티칼스, 인코포레이티드
Publication of KR20230003308A publication Critical patent/KR20230003308A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
KR1020227043234A 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도 Ceased KR20230003308A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
US62/471,484 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use
KR1020197030354A KR20200003791A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030354A Division KR20200003791A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Publications (1)

Publication Number Publication Date
KR20230003308A true KR20230003308A (ko) 2023-01-05

Family

ID=61873991

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227043234A Ceased KR20230003308A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도
KR1020197030354A Ceased KR20200003791A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197030354A Ceased KR20200003791A (ko) 2017-03-15 2018-03-15 듀테트라베나진의 유사체, 이의 제조 및 용도

Country Status (20)

Country Link
US (4) US11813232B2 (https=)
EP (1) EP3596077A1 (https=)
JP (3) JP7608050B2 (https=)
KR (2) KR20230003308A (https=)
CN (1) CN110709398A (https=)
AR (1) AR111182A1 (https=)
AU (2) AU2018236336B2 (https=)
BR (1) BR112019018966A2 (https=)
CA (1) CA3056612A1 (https=)
CL (1) CL2019002629A1 (https=)
CO (1) CO2019011271A2 (https=)
EA (1) EA201992168A1 (https=)
IL (1) IL269132A (https=)
MX (1) MX2019010913A (https=)
PE (1) PE20191819A1 (https=)
SG (1) SG11201908477QA (https=)
TW (1) TWI772382B (https=)
UA (1) UA127052C2 (https=)
WO (1) WO2018170214A1 (https=)
ZA (1) ZA201906326B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування
TWI784220B (zh) 2018-12-13 2022-11-21 美商奧斯拜客斯製藥有限公司 腦性麻痺運動障礙之治療方法
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US11311488B2 (en) * 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EA201791466A1 (ru) * 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування

Also Published As

Publication number Publication date
EA201992168A1 (ru) 2020-03-16
JP7631572B2 (ja) 2025-02-18
AU2018236336B2 (en) 2022-02-24
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
JP2023010754A (ja) 2023-01-20
BR112019018966A2 (pt) 2020-04-22
US20220040170A1 (en) 2022-02-10
MX2019010913A (es) 2020-01-20
TW201840317A (zh) 2018-11-16
EP3596077A1 (en) 2020-01-22
AU2022203369A1 (en) 2022-06-09
AU2022203369B2 (en) 2024-04-04
PE20191819A1 (es) 2019-12-27
WO2018170214A1 (en) 2018-09-20
US20200016148A1 (en) 2020-01-16
UA127052C2 (uk) 2023-03-29
US20220088006A1 (en) 2022-03-24
CA3056612A1 (en) 2018-09-20
CN110709398A (zh) 2020-01-17
KR20200003791A (ko) 2020-01-10
CO2019011271A2 (es) 2020-02-28
US11813232B2 (en) 2023-11-14
JP2020510073A (ja) 2020-04-02
IL269132A (en) 2019-11-28
US11179386B2 (en) 2021-11-23
TWI772382B (zh) 2022-08-01
JP7608050B2 (ja) 2025-01-06
NZ757789A (en) 2024-08-30
JP2024050724A (ja) 2024-04-10
AR111182A1 (es) 2019-06-12
US20180263972A1 (en) 2018-09-20
US12502385B2 (en) 2025-12-23
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
JP7631572B2 (ja) デューテトラベナジンの類似体、その調製及び使用
US9339469B2 (en) R(+)-N-methyl-propargyl-aminoindan
KR20130041193A (ko) 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
KR20140023872A (ko) 중수소 농축 라사길린
KR20140074388A (ko) 라사길린 시트라마이드
CN102458435A (zh) 认知衰退的抑制剂
KR20140090996A (ko) R(+)-n-폼일-프로파길-아미노인단
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
EP2094675B1 (en) A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
HK40018479A (en) Analogs of deutetrabenazine, their preparation and use
EA044519B1 (ru) Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством
TW202542164A (zh) 治療過動性運動障礙之化合物
Groton Bruce M. Johnson and Pei-Tei L. Chang
NZ624206B2 (en) R(+)-n-formyl-propargyl-aminoindan

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221208

Application number text: 1020197030354

Filing date: 20191015

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221214

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20221214

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230531

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I